Ekspresi CD3 dan CD26 pada Limfosit T sebagai Biomarker Potensial Penyakit Systemic Lupus Erythematosus

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease that is frequently found in women and characterized by hyperautoreactivity of T and B cells. In the immune system, expressions of CD 3 and CD26 (as co-stimulatory molecule) are related to T cells activation and migration. Co-expression of CD3 and CD26 in SLE patients has not been determined. The aim of this study was to investigate the co-expression of CD3 and CD26 in blood and T cell culture of SLE patients. This was an analytical descriptive study with a retrospective approach. This study was performed at the Biomedical laboratory, Faculty of Medicine, Sebelas Maret University, for five months (May–September 2012). SLE diagnosis was determined by using the criteria from the American College of Rheumatology (ACR). Vein blood was collected from three female patients with SLE and two healthy female controls. T cells isolated from the blood were cultured and stimulated with 1 µg/mL phytohaemmaglutinin (PHA). Flow cytometry was used to determine the coexpression of CD3 and CD26. CD26 enzyme activities in T cell culture were spectrophotometrically measured using H-Gly-Pro pNA substrate. Collected data were then analyzed using Student’s t test. Decreased coexpression of CD3 and CD26 was lower in blood samples and T cell cultures of SLE female patients than in control. Meanwhile, CD26 enzyme activities in SLE T cell cultures were higher than control (0.042 vs 0.030 U/mL) but no statistical difference was found (p>0.05). In conclusion, there is a decreased coexpression of CD3 and CD26 in blood circulation and T cell cultures subtype CD4+. CD3 and CD26 in SLE patients could be a prospective biomarker. Further research is required to unravel the roles of CD3 and CD26 in SLE pathogenesis.

Keywords

• CD3
• CD26
• systemic lupus erythematosus (SLE)